Zealand Pharma A/S (CO:ZEAL) — Market Cap & Net Worth
Market Cap & Net Worth: Zealand Pharma A/S (ZEAL)
Zealand Pharma A/S (CO:ZEAL) has a market capitalization of $3.36 Billion (Dkr21.48 Billion) as of July 31, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #4506 globally and #29 in its home market, demonstrating a 3.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zealand Pharma A/S's stock price Dkr304.90 by its total outstanding shares 70437463 (70.44 Million). See how much does Zealand Pharma A/S reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Zealand Pharma A/S Market Cap History: 2015 to 2026
Zealand Pharma A/S's market capitalization history from 2015 to 2026. Data shows growth from $1.67 Billion to $3.36 Billion (5.89% CAGR).
Zealand Pharma A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zealand Pharma A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.56x
Zealand Pharma A/S's market cap is 0.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.80x
Zealand Pharma A/S's market cap is 0.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.17 Billion | $234.78 Million | -$153.91 Million | 5.00x | N/A |
| 2017 | $936.74 Million | $139.78 Million | -$272.27 Million | 6.70x | N/A |
| 2018 | $908.09 Million | $37.98 Million | $581.28 Million | 23.91x | 1.56x |
| 2019 | $2.59 Billion | $41.33 Million | -$571.54 Million | 62.76x | N/A |
| 2020 | $2.43 Billion | $353.31 Million | -$846.73 Million | 6.88x | N/A |
| 2021 | $1.60 Billion | $292.57 Million | -$1.02 Billion | 5.47x | N/A |
| 2022 | $2.22 Billion | $103.99 Million | -$965.61 Million | 21.34x | N/A |
| 2023 | $4.11 Billion | $342.79 Million | -$703.74 Million | 12.00x | N/A |
| 2024 | $7.89 Billion | $62.69 Million | -$1.08 Billion | 125.78x | N/A |
| 2025 | $5.14 Billion | $9.21 Billion | $6.46 Billion | 0.56x | 0.80x |
Competitor Companies of ZEAL by Market Capitalization
Companies near Zealand Pharma A/S in the global market cap rankings as of July 31, 2026.
Key companies related to Zealand Pharma A/S by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Zealand Pharma A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, Zealand Pharma A/S's market cap moved from $1.67 Billion to $ 3.36 Billion, with a yearly change of 5.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr3.36 Billion | -34.63% |
| 2025 | Dkr5.14 Billion | -34.81% |
| 2024 | Dkr7.89 Billion | +91.72% |
| 2023 | Dkr4.11 Billion | +85.30% |
| 2022 | Dkr2.22 Billion | +38.80% |
| 2021 | Dkr1.60 Billion | -34.22% |
| 2020 | Dkr2.43 Billion | -6.29% |
| 2019 | Dkr2.59 Billion | +185.68% |
| 2018 | Dkr908.09 Million | -3.06% |
| 2017 | Dkr936.74 Million | -20.19% |
| 2016 | Dkr1.17 Billion | -29.70% |
| 2015 | Dkr1.67 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Zealand Pharma A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.36 Billion USD |
| MoneyControl | $3.36 Billion USD |
| MarketWatch | $3.36 Billion USD |
| marketcap.company | $3.36 Billion USD |
| Reuters | $3.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more